Clinical trials: Colon Disease
Colorectal Cancer
Phase I Study of Dalotuzumab (MK-0646) in Combination With Cetuximab and Irinotecan in Participants With Colorectal Cancer (MK-0646-016)
The purposes of this study were to assess the safety, tolerability, pharmacokinetic interactions, and the Human Anti-Human Antibody of dalotuzumab in combination with cetuximab and irinotecan in participants with advanced or…
- Trial name
- NCT00925015
- Testing
- Dalotuzumab 10 mg/kg, Cetuximab, Irinotecan
- Volunteers
- 20 people
- Sponsor
- Merck Sharp & Dohme LLC
Colorectal Adenoma, Colorectal Carcinoma
Vaccine Therapy in Treating Patients With Newly Diagnosed Advanced Colon Polyps
This randomized phase II clinical trial studies how well MUC1 peptide-poly-ICLC adjuvant vaccine works in treating patients with newly diagnosed advanced colon polyps (adenomatous polyps).
- Conditions
- Colorectal Adenoma, Colorectal Carcinoma, Colorectal Conventional Adenoma With Severe Dysplasia, Colorectal Tubulovillous Adenoma
- Trial name
- NCT02134925
- Testing
- Laboratory Biomarker Analysis, MUC1 Peptide-Poly-ICLC Vaccine, Quality-of-Life Assessment
- Where
- 7 sites in United States, Puerto Rico
- Volunteers
- 110 people
- Sponsor
- National Cancer Institute (NCI)
Colon Cancer, Rectal Cancer
Genistein in Treatment of Metastatic Colorectal Cancer
Colorectal neoplasms are the third most common malignancies in the United States. Patients with metastatic (stage IV) colorectal cancer have a median life expectancy of 2 years.
- Conditions
- Colon Cancer, Rectal Cancer, Colorectal Cancer
- Trial name
- NCT01985763
- Testing
- Genistein
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- Sofya Pintova
Colorectal Cancer, Metastases
Evaluating Panitumumab (ABX-EGF) Plus Best Supportive Care Versus Best Supportive Care in Patients With Metastatic Colorectal Cancer
The purpose of this study is to determine that panitumumab, using the proposed regimen, will safely increase progression free survival in patients with metastatic colorectal cancer who have failed available treatment options…
- Trial name
- NCT00113763
- Testing
- Best supportive care, Panitumumab
- Volunteers
- 463 people
- Sponsor
- Amgen
Colorectal Cancer
Reolysin in Combination With FOLFOX6 and Bevacizumab or FOLFOX6 and Bevacizumab Alone in Metastatic Colorectal Cancer
The purpose of this study is to find out if giving reolysin in combination with FOLFOX6/ bevacizumab can offer better results than standard therapy with FOLFOX6/ bevacizumab.
- Trial name
- NCT01622543
- Testing
- Folfox plus Bevacizumab and reolysin, Folfox plus Bevacizumab
- Where
- 10 sites in Canada
- Volunteers
- 109 people
- Sponsor
- Canadian Cancer Trials Group
Ulcerative Colitis
Endovenous Corticosteroid Pulses in Moderate Ulcerative Colitis
The purpose of this study is to determine the efficacy of high-dose corticosteroid pulses added to conventional oral corticosteroid course for moderate flares of ulcerative colitis.
- Trial name
- CECUM (NCT02921555)
- Testing
- Methylprednisolone, Prednisone
- Where
- 29 sites in Spain
- Volunteers
- 75 people
- Sponsor
- Grupo Espanol de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa
Cetuximab-induced Papulopustular (Acneiform) Rash Who Have, Metastatic Colorectal Cancer or Head and Neck Squamous Cell Carcinoma
Study of Prophylactic Topical Dapsone 5% Gel Versus Moisturizer for Cetuximab-induced Papulopustular (Acneiform) Rash in Patients With mCRC or HNSCC Without Previous or Concurrent RT
The purpose of this study is to see if the investigators can prevent or reduce the severity of the Cetuximab-related acne rash. Two different topical agents will be applied to the skin.
- Trial name
- NCT01931150
- Testing
- Topical Dapsone 5% Gel, Moisturizer, oral antibiotics
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Metastatic Colorectal Cancer
A Study of Vismodegib (GDC-0449, Hedgehog Pathway Inhibitor) With Concurrent Chemotherapy and Bevacizumab As First-Line Therapy for Metastatic Colorectal Cancer
This was a randomized, placebo-controlled, double-blind study of vismodegib (GDC-0449) added to biochemotherapy standard-of-care regimens for metastatic colorectal cancer (CRC), with treatment until disease progression.
- Trial name
- NCT00636610
- Testing
- Vismodegib 150 mg, Bevacizumab, Modified FOLFOX
- Volunteers
- 199 people
- Sponsor
- Genentech, Inc.
Colorectal Cancer
TMZ + Olaparib for MGMT Hypermethylated Colorectal Cancer
This is a Phase II, non-randomized, open-label study to evaluate temozolomide in combination with olaparib in patients with MGMT promoter hypermethylated advanced colorectal cancer.
- Trial name
- NCT04166435
- Testing
- Temozolomide + Olaparib
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Yale University
Head and Neck Cancer, Colon Cancer
A Dose Finding Study of Eribulin Mesylate and Cetuximab For Patients With Advanced Head and Neck and Colon Cancer
The purpose of this study is to determine if the full dose of eribulin mesylate can be safely given with the full dose of cetuximab.
- Trial name
- NCT01744340
- Testing
- Head and neck, Colon- Closed as of May 2014
- Where
- 4 sites in United States
- Volunteers
- 23 people
- Sponsor
- howard safran
CRC (Colorectal Cancer)
Study of Ruxolitinib in Colorectal Cancer Patients
The purpose of this study was to determine if ruxolitinib, in combination with regorafenib, is safe and effective in the treatment of metastatic colorectal cancer.
- Trial name
- NCT02119676
- Testing
- Ruxolitinib, Regorafenib
- Where
- 86 sites in United States, Australia and 6 more
- Volunteers
- 396 people
- Sponsor
- Incyte Corporation
Colon Cancer, Rectal Cancer
Exploratory Study Of The ERCC-1 Gene
This study is for patients with advanced or stage II and III colon or rectal cancer. The primary purpose of this research study is to determine if a particular protein in the patient's blood will change when they receive…
- Trial name
- NCT00846482
- Testing
- Oxaliplatin
- Where
- 2 sites in United States
- Volunteers
- 64 people
- Sponsor
- Albert Einstein College of Medicine
Colorectal Cancer
An Observational Study of Xeloda (Capecitabine) in Patients With Metastatic Colorectal Cancer (AXIOM)
This prospective observational study will evaluate the safety and efficacy of Xeloda (capecitabine) administered in monotherapy in patients with metastatic colorectal cancer.
- Trial name
- NCT01697462
- Where
- 5 sites in Serbia
- Volunteers
- 258 people
- Sponsor
- Hoffmann-La Roche
Clostridium Difficile Infection
Effect of Acid Suppression Medication on Pediatric Microbiome
The colonic microbiome is essential in health and disease, and is highly dynamic during the first several years of life. Proton pump inhibitors (PPIs) and histamine-2 receptor antagonists (H2RAs) are widely used in children, but…
- Trial name
- NCT02016820
- Testing
- Omeprazole (suspension), Lifestyle Modification
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Columbia University
Metastatic Colorectal Cancer
A Study Of PF-05212384 Plus Irinotecan Vs Cetuximab Plus Irinotecan In Patients With KRAS And NRAS Wild Type Metastatic Colorectal Cancer
This study will investigate whether the combination of PF-05212384 plus Irinotecan improves progression free survival in patients with KRAS and NRAS wild type metastatic colorectal cancer when compared with the combination of…
- Trial name
- NCT01925274
- Testing
- PF-05212384, irinotecan, Cetuximab
- Where
- 32 sites in United States, Japan and 2 more
- Volunteers
- 19 people
- Sponsor
- Pfizer
Colorectal Neoplasms
Aflibercept +/- LV5FU2 in First Line of Non-resectalbe Metastatic Colorectal Cancers
This is what the FFCD 11-01 - PRODIGE 25 trial proposes to study, as a preliminary for strategic studies evaluating the usefulness of including targeted therapeutics from the first line with aflibercept +/- LV5FU2.
- Trial name
- FOLFA (NCT02384759)
- Testing
- aflibercept, LV5FU2
- Where
- 58 sites in France
- Volunteers
- 117 people
- Sponsor
- Federation Francophone de Cancerologie Digestive
Head and Neck Cancer Squamous Cell Carcinoma, Non-small Cell Lung Cancer
Study of ADCT-301 in Patients With Selected Advanced Solid Tumors
This study evaluates ADCT-301 in patients with Selected Advanced Solid Tumors. Patients will participate in a Treatment Period with 3-week cycles and a Follow-up Period every 12 weeks for up to 1 year after treatment…
- Conditions
- Head and Neck Cancer Squamous Cell Carcinoma, Non-small Cell Lung Cancer, Gastric Cancer, Esophageal Cancer
- Trial name
- NCT03621982
- Testing
- ADCT-301, Pembrolizumab
- Where
- 9 sites in United States, Belgium and 1 more
- Volunteers
- 78 people
- Sponsor
- ADC Therapeutics S.A.
Metastatic Colorectal Cancer
Study of GVAX (With CY) and Pembrolizumab in MMR-p Advanced Colorectal Cancer
This study will be looking at the objective response rate (ORR) as measured by RECIST in in patients with mismatch repair-proficient (MMR-p), advanced colorectal cancer that treated with CY/GVAX in combination with Pembrolizumab.
- Trial name
- NCT02981524
- Testing
- CY, GVAX, Pembrolizumab
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Colorectal Neoplasms
Levocetirizine + Capecitabine + Bevacizumab for Patients With Refractory Colorectal Cancer
This randomized phase II trial studies how giving a drug called levocetirizine to patients with colorectal cancer affects their tumor response to capecitabine and bevacizumab.
- Trial name
- NCT01722162
- Testing
- Bevacizumab, Capecitabine, Levocetirizine
- Where
- United States
- Volunteers
- 47 people
- Sponsor
- Washington University School of Medicine
Cancer Colon
Perioperative Iron for Colorectal Cancer (PICoC Study)
The PICoC study aims to investigate whether oral ferric maltol given postoperatively offers an improvement in patient and clinician reported outcomes compared to standard care.
- Trial name
- PICoC (NCT05177484)
- Testing
- oral ferric maltol
- Where
- United Kingdom
- Volunteers
- 40 people
- Sponsor
- The Royal Wolverhampton Hospitals NHS Trust
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.